文献速递妇科肿瘤

FORWARD I:Mirvetuximab soravtansine对比化疗治疗铂耐药卵巢癌的III期随机试验主要分析

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
PubMed 文献 · Ann Oncol · 2021-03-02

FORWARD I是一项开放标签III期随机试验,比较MIRV与研究者选择的化疗在铂耐药上皮性卵巢癌患者中的疗效。主要终点PFS在ITT人群(HR 0.98,P=0.897)和FRα高表达人群(HR 0.69,P=0.049)均未达到统计学显著。在FRα高表达人群中,MIRV在ORR、CA-125反应和患者报告结局等次要终点上均优于化疗,且安全性更易管理。

要点

  • ITT人群PFS无显著获益(HR 0.98,P=0.897)。
  • FRα高表达人群PFS未达显著(HR 0.69,P=0.049)。
  • FRα高表达人群ORR 24% vs 10%,CA-125反应53% vs 25%。

核心结论

  • 在铂耐药上皮性卵巢癌中,MIRV相比化疗未显著改善PFS。
  • 次要终点一致倾向于MIRV,尤其在FRα高表达患者中。
  • MIRV安全性特征与化疗不同且更易管理。

研究设计与样本

  • 随机、开放标签、III期研究FORWARD I。
  • 纳入1-3线既往治疗且FRα表达阳性的铂耐药上皮性卵巢癌患者。
  • 按2:1随机分配至MIRV(6 mg/kg,调整理想体重)或化疗(紫杉醇、聚乙二醇脂质体多柔比星或拓扑替康)。
  • 共366例患者随机,243例接受MIRV,109例接受化疗。
  • 主要终点为PFS(RECIST 1.1,盲法独立中心审查),在ITT人群和预设FRα高表达人群中评估。

主要发现

  • ITT人群PFS:HR 0.98,P=0.897。
  • FRα高表达人群PFS:HR 0.69,P=0.049。
  • FRα高表达人群客观缓解率:24% vs 10%。
  • FRα高表达人群CA-125反应:53% vs 25%。
  • FRα高表达人群患者报告结局:27% vs 13%。

关键数值与推荐

  • FRα高表达人群客观缓解率24% vs 10%。
  • FRα高表达人群CA-125反应53% vs 25%。
  • FRα高表达人群患者报告结局27% vs 13%。
  • ≥3级治疗相关不良事件:25.1% vs 44.0%。
  • 导致剂量降低的事件:19.8% vs 30.3%;导致治疗终止的事件:4.5% vs 8.3%。

临床怎么用

  • MIRV未在ITT人群显著改善PFS,不宜作为铂耐药卵巢癌全体人群的默认替代。
  • FRα高表达患者可能从MIRV获得更高的缓解率和更好的安全性,需关注FRα表达检测。
  • MIRV的毒性谱与化疗不同,≥3级不良事件和剂量调整事件更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The randomized, open-label, phase III study FORWARD I compared MIRV and investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Eligible patients with 1-3 prior lines of therapy and whose tumors were positive for FRα expression were randomly assigned, in a 2 : 1 ratio, to receive MIRV (6 mg/kg, adjusted ideal body weight) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary endpoint was progression-free survival [PFS, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, blinded independent central review] in the intention-to-treat (ITT) population and in the prespecified FRα high population. RESULTS: A total of 366 patients were randomized; 243 received MIRV and 109 received chemotherapy. The primary endpoint, PFS, did not reach statistical significance in either the ITT [hazard ratio (HR), 0.98, P = 0.897] or the FRα high population (HR, 0.69, P = 0.049). Superior outcomes for MIRV over chemotherapy were observed in all secondary endpoints in the FRα high population including improved objective response rate (24% versus 10%), CA-125 responses (53% versus 25%), and patient-reported outcomes (27% versus 13%). Fewer treatment-related grade 3 or higher adverse events (25.1% versus 44.0%), and fewer events leading to dose reduction (19.8% versus 30.3%) and treatment discontinuation (4.5% versus 8.3%) were seen with MIRV compared with chemotherapy. CONCLUSIONS: In patients with platinum-resistant EOC, MIRV did not result in a significant improvement in PFS compared with chemotherapy. Secondary endpoints consistently favored MIRV, particularly in patients with high FRα expression. MIRV showed a differentiated and more manageable safety profile than chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021. PMID: 33667670. doi:10.1016/j.annonc.2021.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。